SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September:

5th HKEX Biotech Summit 2022


Panel Discussion: Thursday, September 1, 2022, 3:10 p.m. HKT

Location: Hong Kong

Citi’s 17th Annual BioPharma Conference


Fireside Chat: Thursday, September 8, 2022, 8:50 a.m. ET

Location: Boston, MA

3rd Annual Jefferies Asia Forum


Presentation: Friday, September 9, 2022, 11:00 a.m. HKT

Morgan Stanley 20th Annual Global Healthcare Conference


Meetings: Wednesday, September 14, 2022

Location: New York

Cantor Oncology, Hematology & HemeOnc Conference


Meetings: Wednesday, September 28, 2022

Location: New York

Webcast links of the presentations will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. The archived replay will be viewable after the events for 90 days.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit

www.zailaboratory.com

or follow us at

www.twitter.com/ZaiLab_Global

.

For more information, please contact:

Investor Relations:

Lina Zhang

+86 136 8257 6943


[email protected]

Media:

Danielle Halstrom / Xiaoyu Chen

+1 (215) 280-3898 / +86 185 0015 5011


[email protected]

/

[email protected]

Zai Lab Limited

Source: Zai Lab Limited